Lifetime Patient Management Greater Expectations: Is TAVI Rising to The Challenge?
Published: 24 March 2023
-
Views:
2105 -
Likes:
7
-
Views:
2105 -
Likes:
7
Overview
This symposium, part of Transcatheter Interventions Online 2023, and chaired by Prof David Hildick-Smith (Brighton & Sussex University Hospitals NHS Trust, Brighton, UK), featured a panel discussion on the latest data on durability and clinical outcomes, an analysis of how TAVI is changing and possible future options for patients with aortic valve disease. The symposium also featured a minimalistic TAVI live case performed by Prof Stefan Toggweiler (Lucerne Cantonal Hospital, Lucerne, CH).
The live version of 'Lifetime Patient Management Greater Expectations: Is TAVI Rising to The Challenge?' was CME-accredited. This on-demand version is not.
Learning Objectives:
- Recall the latest data on durability and clinical outcomes for TAVI
- Understand how TAVI is advancing and become aware of future treatment options for lifetime management of patients with aortic valve disease
- Become more confident using TAVI in cases with complex anatomy
Target Audience
- Interventional Cardiologists
- Surgeons with an interest in transcatheter treatment strategies for coronary and structural heart disease
- Interventional Cardiology Nurses
More from this programme
Part 1
Welcome & Introduction
Prof David Hildick-Smith introduces the symposium session and the panel.
1 session | |
Welcome & Introduction | Watch now |
Part 2
Live Case
Part 3
Data from 2022/23: What’s new in TAVI
Prof Giuseppe Tarantini presents what's new in TAVI, including data from 2022/23.
Part 4
Live Case
Prof Stefan Toggweiler shows the valve implantation procedure.
Part 5
How Is TAVI Advancing to Meeting Lifelong Management Goals
Prof Lars Søndergaard presents on how TAVI is advancing to meet lifelong management goals.
Part 6
Discussion & Close
Prof Hildick-Smith closes the symposium.
1 session | |
Discussion & Close | Watch now |
Faculty Biographies
David Hildick-Smith
Prof David Hildick-Smith is Professor of Interventional Cardiology and Consultant Cardiologist at the Sussex Cardiac Centre - the Regional Specialist Unit. He is Director of the Cardiac Research, ex-Treasurer of the British Cardiovascular Interventions Society, and, with more than 20 years experience of Interventional Cardiology, is considered one of the country's leading experts in management of Cardiovascular complaints.
A pioneer of Interventional Cardiology, David is recognised internationally as a leader in cardiovascular diagnosis and treatment.
Giuseppe Tarantini
Prof Giuseppe Tarantini is the Head of the Interventional Cardiology Unit within the Department of Cardiac, Thoracic, and Vascular Sciences at the University of Padua Medical School, Padua, IT. He is a globally recognised researcher specialising in ischemic heart disease, structural heart disease, and cardiomyopathies.
Prof Tarantini serves as the primary operator for a diverse array of interventional procedures, encompassing coronary interventions (including atherectomies), peripheral interventions (such as carotid and renal procedures), and structural heart interventions (involving ASDs, PFOs, TAVI, and AVP).
In addition to his clinical work, Prof Tarantini is a distinguished faculty member at various international conferences, including Transcatheter Cardiovascular Therapeutics (TCT), the Congresso della Societa Italiana di Cardiologia Invasiva (SICI-GISE), Euro PCR, and the European Society of Cardiology (ESC). He boasts a publication record of 245 clinical…
Lars Søndergaard
Professor Lars Søndergaard is a consultant cardiologist at Rigshospitalet – Copenhagen, Denmark. Professor of Cardiology at University of Copenhagen, he published over 300 peer reviewed articles, and more than 15 textbook chapters. His research interests are focused on adults with congenital heart diseases and catheter-based heart valve interventions, as well as congenital and structural heart diseases. He led the first-in-human transcatheter mitral valve implantation (CardiAQ) in 2012 and he actively participated to several trials, including NOTION (transcatheter vs. surgical aortic valve replacement in patients with aortic stenosis and low surgical risk), and the REDUCE randomised trial (PFO vs anti-platelet therapy after cryptogenic stroke).
Stefan Toggweiler
Stefan Toggweiler, PD Dr med, is the head of interventional valve therapy at Heart Center Lucerne.
Comments